Zoetis Inc. (ZTS)
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
The animal-health company missed first-quarter earnings estimates.
Zoetis (ZTS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zoetis (ZTS) Misses Q1 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.53 per share, missing the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.48 per share a year ago.
Curious about Zoetis (ZTS) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
Zoetis Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zoetis (ZTS) reached $116.65 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
Here's Why Zoetis (ZTS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IDEXX Laboratories Vs. Zoetis: A Pre-Earnings Comparison
Idexx Laboratories, Inc. and Zoetis Inc. are dominant players in animal health, but IDXX outperforms due to superior capital efficiency and recurring revenue flywheel. ZTS trades at a much lower valuation with solid margins and a dependable pipeline, but requires catalysts—like EPS beats or new approvals—for rerating in 2026. IDXX commands a premium valuation, driven by high ROIC (37–49%) and robust growth in diagnostics, notably its Cancer DX test and InVue DX instrument adoption.
Zoetis (ZTS) Stock Slides as Market Rises: Facts to Know Before You Trade
Zoetis (ZTS) concluded the recent trading session at $119.04, signifying a -1.42% move from its prior day's close.
Citi Just Made Zoetis Its Top Pick With a Buy Rating: Is the Pet Economy Boom the Best Trade of 2026?
One of Wall Street's top firms just gave a thumbs-up to Zoetis (NYSE:ZTS) stock.
